everybody dreams of picking the right penny share for the top.i myself am about to start a new portfolio and would like some ideas from the punters on this forum.

Share for this week winchester(WIE) director buying big profits ?

CSW upbeat results.Good outlook for the future

http://www.sharecast.com/cgi-bin/sharecast/security.cgi?&csi=51050

Regen Therapeutic RGT should see an increase in Sept where if I am guessing right the interim results should be accompanied by some sort of statement about the ongoing prospects for Collostinin. Some I am sure will grab the quick buck then but there are a lot of people in for the real gains which hopefully should come next year.

Puzzling that I topped up this morning with 198,720 shares at 3.10 and yet it is showing on the site as a sell. I don't think the sell price has yet reached 3.10 so I suspect mine and a couple of others have been wrongly entered so the buys should look far more positive than they do at present.

Fingers crossed for the long term and I hope we don't see too much shorting in September to upset the applecart.

Gantenbrink

No ones mentioned NMT??? 130% in the last two weeks and still rising today.....

ITU is my fave. Read the posts on it then check into the shares mag blue sky portfolio........it is on their list of stocks they think could go up ten times. I didnt buy it for that reason though.....had it before then when IC mag did an article saying it could achieve explosive growth.
Have alook.

Check out NES. They have risen every single day for the last 9 nine days in a row and are due to announce results on 2nd September. It look as if there could be good news on the horizon - and if there isn't then why's everyone buying them everyday??? Get in now before announcement day but DYOR of course - if I knew how, I would have pasted a graph for you all to look at.

Another tip for medium term investment is ANW - check it out. Hardly ever goes down - either stays put or goes up. Has been averaging nearly 1% a day since I bought them on 2nd July. It is a fund investing in Thailand and if anyone knows how well things are going over there economically at the moment then you'll understand why they keep going up!! So if your fed up of volatile shares then keep this one in your portfolio just ticking over in the background. You'll be suprised how quickly the weeks go by and all those 1%'s have added up to something quite decent!!
Also those nice ANW people frequently release net asset value figures so that you can make sure the fund value is going up OK - a bit like someone giving you regular confirmation that your share value is inline with company performance!

PS Also ANW is at position 13 of the higest climbing shares of the last ten days - I read it somewhere on this site....

My penny stocks of this month are
Retail Decisions,
NSB Retail,
Harrier Group,
These three are expecting good results end of the month...You have been warned...if they surge from here..


New Media Spark, and Redstone Telecom are others I generally folow and now Hold...

AIT is a larger share now, but bought at 13p...now it's 79p to buy...!
Read my thread and you may be surprised, it only just started as far as the market is concerned...for sure I expect it to go much further...it did get to 450 quid at one point...!

Anymore I 'll post later...

jules.

COR - ahead of results (with Asda promoting Noddy)
SPS - results imminent (plus rumoured Motorola deal and more)
MIC - newly floated with big prospects and good connections
JKX - one to hold all year and beyond
NOP - ditto

Added two yesterday.SYM-rumours of deals with tesco,walmart and bt.See thread on bb.RDN-on recovery hopes.

MLS - This was the item that triggered the current breakout last week:

LONDON (AFX) - Medical Solutions PLC, the cancer and pathology services
group, said The Doctors Laboratory, the leading provider of private cervical
screening in the UK, has stated that they are adopting Medical Solutions'
SurePath for their LBC screening.
The SurePath system will be supplied by Medical Solutions in the UK under
licence from TriPath Imaging Inc.
Medical Solutions chief executive Charles Green said the group now awaits
the NICE (the National Institute of Clinical Excellence) report issuing their
final guidance to the NHS, after their preliminary report recommended the use of
liquid based cytology within the NHS. This report is expected in September.
newsdesk@afxnews.com
slm/

See impressive bb comment here since then and on various BBs.

Interims due mid-Sept.

Newmark (NWT) might be about to take off. Price has been flat since April but results are due out soon and MM just bought a chunck ahead of weekend press. Directors were buying back in the spring. Bit of cash on balance sheet. Not done any more research but did punt a few earlier. With Mkt cap of only 3.8m, could sure fly on good news or a penny guide tip, etc.

Mole.

Anybody been watching WMS? Results out beginning of Sept. Recent Contract wins and the price has been steadily rising over the past couple of months.

Here is a great tip, ASOS (or AsSeenOnScreen). Huge previous increases in turnover and company is expected to announce a small profit this year. Shares are currently at a low of 4.88p and i can see them rising substantially in the coming months. STRONG BUY!!!!

CFP could be an interesting recovery play as more companies look to list on the stock exchange.Some activity and weird trades today.

My tips are : YOO, BED, IQE, RGT and OXB. Most of these have had a mention I notice on this thread already, and all have had a good run in the last few mths. The most exciting co. with bags of potential has got to be OXB though with lots of positive news flow and wildly undervalued in my opinion - it's my favourite biotech and every portfolio should have some exposure to that sector. Obviously I have an interest but take a look at the news, and their website DYOR and it should be rewarded.

for the next week or two, my moneys on Retail decisions...

DYOR as always..

Check out Retail Dicisions thread NOW!

And as by majic :
Oxford Biomedica PLC
28 August 2003


28 August 2003


For further information, please contact:



Oxford BioMedica plc
Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000


City/Financial Enquiries:
Mike Wort, James Chandler: Beattie Financial Tel: +44 (0) 7730 418 745


Scientific/Trade Press Enquiries:
Sue Charles, Katja Stout: Northbank Communications Tel: +44 (0)20 7886 8150



CANCER RESEARCH UK SUPPORTS ADDITIONAL TROVAX PHASE II TRIAL IN COLORECTAL
CANCER


Oxford, UK: 28 August 2003 - Oxford BioMedica announced today that Cancer
Research UK has agreed to conduct and sponsor an open label Phase II trial with
Oxford BioMedica's leading cancer immunotherapy product, TroVax(R), in
colorectal cancer patients who have liver metastases. The decision by Cancer
Research UK follows extensive review of the successful Phase I/II data of TroVax
in colorectal cancer patients. This study is in addition to the two ongoing
Phase II trials with TroVax in colorectal cancer alongside chemotherapy, and the
planned trials in renal and breast cancer.


The patient population in the Cancer Research UK Phase II trial will comprise
twenty Stage IV colorectal cancer patients who are to undergo surgery for
resectable liver metastases. Patients will receive injections of TroVax followed
by surgery approximately two weeks later. Biopsies of the tumour will be taken
at surgery and analysed for TroVax stimulated immune activity. Further
vaccinations will be given after surgery. Patients' management will then
continue as standard, usually including adjuvant chemotherapy. Patients will be
followed after the final vaccination to assess immune responses and toxicity and
then monitored over the longer term for clinical benefit.



Commenting on the announcement, Oxford BioMedica's chief executive, Professor
Alan Kingsman said, 'Cancer Research UK is one of the world's leading cancer
research organisations and is committed to the development of better cancer
treatments for patients. Their involvement in this project provides further
validation of Oxford BioMedica's advanced cancer immunotherapeutic'



Ends-



Notes to editors



1. Oxford BioMedica



Based in Oxford, UK, Oxford BioMedica is a biopharmaceutical company
specialising in the development of novel gene-based therapeutics for the
treatment of cancer, neuro-degenerative disease and other disorders with major
unmet clinical needs. The Company was established in 1995 as a spin out from
Oxford University, and is listed on the London Stock Exchange.



In addition to its technical research skill-base, Oxford BioMedica has in-house
clinical, regulatory and manufacturing know-how. The development pipeline
includes two novel anti-cancer products in clinical trials and a gene-based
treatment for Parkinson's disease, which is in late preclinical studies. The
Company is underpinned by an extensive preclinical and research portfolio and
over 70 patent families, about quarter of which are issued.



TroVax(R), which is Oxford BioMedica's lead cancer immunotherapy product, is in
Phase II trials for colorectal cancer (see below). MetXia(R) is Oxford
BioMedica's lead gene-based cancer therapeutic. The product is based on a highly
engineered retrovirus gene delivery system expressing a specific human
cytochrome P450 gene. MetXia converts the tumour into a 'drug factory', enabling
increased local production of the anti-tumour, cytotoxic derivative of the
pro-drug cyclophosphamide. MetXia is potentially useful in the treatment of all
solid tumours and their metastases, particularly those where cyclophosphamide is
commonly used. MetXia is being investigated in a Phase I/II trial in breast
cancer, and regulatory submissions are under review for trials in pancreactic
cancer.



Oxford BioMedica has a wholly-owned subsidiary in San Diego, USA. Oxford
BioMedica has corporate collaborations with Wyeth, Intervet, Aliga
Pharmaceuticals, Amersham, Arius Research and Viragen.



Further information is available at
http://www.oxfordbiomedica.co.uk


2. TroVax



TroVax is Oxford BioMedica's leading cancer immunotherapy product. It is
designed specifically to stimulate an anti-cancer immune response and has
potential application in most solid tumour types. TroVax targets the tumour
antigen 5T4, which is broadly distributed throughout a wide range of solid
tumours. The presence of 5T4 is correlated with poor prognosis. The product
consists of a poxvirus (MVA) gene transfer system, which delivers the gene for
5T4 and stimulates a patient's body to produce an anti-5T4 immune response. This
immune response destroys tumour cells carrying the 5T4 protein.



Two Phase I/II trials with TroVax have been completed in the UK in late-stage
colorectal cancer patients. Following these successful Phase I/II trials, TroVax
has entered two Phase II trials in Stage IV colorectal cancer patients receiving
5FU plus either oxaliplatin or irinotecan. The product is also on target to
enter further trials in colorectal, renal and breast cancer. The renal and
breast cancer trials are to be conducted in the United States under an
Investigational New Drug (IND) application. Data from the first TroVax Phase II
trial is expected to be available by the end of 2003, in readiness for Phase III
trials in colorectal cancer.



3. Cancer Research UK



Cancer Research UK began operating on 4 February 2002 as a result of the merger
between The Cancer Research Campaign and Imperial Cancer Research Fund. Its
vision is to conquer cancer through world-class research. It is the largest
volunteer-supported cancer research organisation in the world with a dedicated
team of 3,000 scientists and an annual scientific spend of more than 176
million. Its objectives, amongst others, are to: carry out world class research
into cancer; develop better treatments for cancer patients; improve the quality
of life of cancer patients; reduce the number of people getting cancer; improve
training and support of cancer research workers; and provide authoritative
information and advocacy on cancer.




This information is provided by RNS
The company news service from the London Stock Exchange